Article Versions Notes

Oguma Y, Hosono M, Okajima K, Inoue E, Nakamatsu K, Doi H, Matsuura T, Inada M, Uehara T, Wada Y, et al. Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer. Radiation. 2022; 2(3):273-284. https://doi.org/10.3390/radiation2030021

Oguma, Yasuo, Makoto Hosono, Kaoru Okajima, Eri Inoue, Kiyoshi Nakamatsu, Hiroshi Doi, Tomohiro Matsuura, Masahiro Inada, Takuya Uehara, Yutaro Wada, and et al. 2022. "Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer" Radiation 2, no. 3: 273-284. https://doi.org/10.3390/radiation2030021

Oguma, Y., Hosono, M., Okajima, K., Inoue, E., Nakamatsu, K., Doi, H., Matsuura, T., Inada, M., Uehara, T., Wada, Y., Ri, A., Yamamoto, Y., Yoshimura, K., Uemura, H., & Nishimura, Y. (2022). Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer. Radiation, 2(3), 273-284. https://doi.org/10.3390/radiation2030021